Cargando…

Design and Optimization of Nanostructured Lipid Carrier Containing Dexamethasone for Ophthalmic Use

The aim of this study was to perform a preformulation study of dexamethasone (DXM)-loaded nanostructured lipid carriers (NLCs) for ocular use. Lipid screening was applied to find the most suitable solid and liquid lipids and surfactant for the NLC formulation. The visual observation was proved with...

Descripción completa

Detalles Bibliográficos
Autores principales: L. Kiss, Eszter, Berkó, Szilvia, Gácsi, Attila, Kovács, Anita, Katona, Gábor, Soós, Judit, Csányi, Erzsébet, Gróf, Ilona, Harazin, András, Deli, Mária A., Budai-Szűcs, Mária
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955972/
https://www.ncbi.nlm.nih.gov/pubmed/31847336
http://dx.doi.org/10.3390/pharmaceutics11120679
_version_ 1783487052461899776
author L. Kiss, Eszter
Berkó, Szilvia
Gácsi, Attila
Kovács, Anita
Katona, Gábor
Soós, Judit
Csányi, Erzsébet
Gróf, Ilona
Harazin, András
Deli, Mária A.
Budai-Szűcs, Mária
author_facet L. Kiss, Eszter
Berkó, Szilvia
Gácsi, Attila
Kovács, Anita
Katona, Gábor
Soós, Judit
Csányi, Erzsébet
Gróf, Ilona
Harazin, András
Deli, Mária A.
Budai-Szűcs, Mária
author_sort L. Kiss, Eszter
collection PubMed
description The aim of this study was to perform a preformulation study of dexamethasone (DXM)-loaded nanostructured lipid carriers (NLCs) for ocular use. Lipid screening was applied to find the most suitable solid and liquid lipids and surfactant for the NLC formulation. The visual observation was proved with XRD measurements for the establishment of the soluble state of DXM. Thermoanalytical measurements indicated that the most relevant depression of the crystallinity index could be ensured when using a 7:3 solid lipid:oil ratio. In order to optimize the NLC composition, a 2(3) full factorial experimental design was used. It was established that each independent factor (lipid, DXM, and surfactant concentration) had a significant effect on the particle size while in the case of entrapment efficiency, the DXM and surfactant concentrations were significant. Lower surfactant and lipid concentrations could be beneficial because the stability and the entrapment efficacy of NLCs were more favorable. The toxicity tests on human cornea cells indicated good ophthalmic tolerability of NLCs. The in vitro drug release study predicted a higher concentration of the solute DXM on the eye surface while the Raman mapping penetration study on the porcine cornea showed a high concentration of nanocarriers in the hydrophylic stroma layer.
format Online
Article
Text
id pubmed-6955972
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69559722020-01-23 Design and Optimization of Nanostructured Lipid Carrier Containing Dexamethasone for Ophthalmic Use L. Kiss, Eszter Berkó, Szilvia Gácsi, Attila Kovács, Anita Katona, Gábor Soós, Judit Csányi, Erzsébet Gróf, Ilona Harazin, András Deli, Mária A. Budai-Szűcs, Mária Pharmaceutics Article The aim of this study was to perform a preformulation study of dexamethasone (DXM)-loaded nanostructured lipid carriers (NLCs) for ocular use. Lipid screening was applied to find the most suitable solid and liquid lipids and surfactant for the NLC formulation. The visual observation was proved with XRD measurements for the establishment of the soluble state of DXM. Thermoanalytical measurements indicated that the most relevant depression of the crystallinity index could be ensured when using a 7:3 solid lipid:oil ratio. In order to optimize the NLC composition, a 2(3) full factorial experimental design was used. It was established that each independent factor (lipid, DXM, and surfactant concentration) had a significant effect on the particle size while in the case of entrapment efficiency, the DXM and surfactant concentrations were significant. Lower surfactant and lipid concentrations could be beneficial because the stability and the entrapment efficacy of NLCs were more favorable. The toxicity tests on human cornea cells indicated good ophthalmic tolerability of NLCs. The in vitro drug release study predicted a higher concentration of the solute DXM on the eye surface while the Raman mapping penetration study on the porcine cornea showed a high concentration of nanocarriers in the hydrophylic stroma layer. MDPI 2019-12-14 /pmc/articles/PMC6955972/ /pubmed/31847336 http://dx.doi.org/10.3390/pharmaceutics11120679 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
L. Kiss, Eszter
Berkó, Szilvia
Gácsi, Attila
Kovács, Anita
Katona, Gábor
Soós, Judit
Csányi, Erzsébet
Gróf, Ilona
Harazin, András
Deli, Mária A.
Budai-Szűcs, Mária
Design and Optimization of Nanostructured Lipid Carrier Containing Dexamethasone for Ophthalmic Use
title Design and Optimization of Nanostructured Lipid Carrier Containing Dexamethasone for Ophthalmic Use
title_full Design and Optimization of Nanostructured Lipid Carrier Containing Dexamethasone for Ophthalmic Use
title_fullStr Design and Optimization of Nanostructured Lipid Carrier Containing Dexamethasone for Ophthalmic Use
title_full_unstemmed Design and Optimization of Nanostructured Lipid Carrier Containing Dexamethasone for Ophthalmic Use
title_short Design and Optimization of Nanostructured Lipid Carrier Containing Dexamethasone for Ophthalmic Use
title_sort design and optimization of nanostructured lipid carrier containing dexamethasone for ophthalmic use
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955972/
https://www.ncbi.nlm.nih.gov/pubmed/31847336
http://dx.doi.org/10.3390/pharmaceutics11120679
work_keys_str_mv AT lkisseszter designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse
AT berkoszilvia designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse
AT gacsiattila designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse
AT kovacsanita designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse
AT katonagabor designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse
AT soosjudit designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse
AT csanyierzsebet designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse
AT grofilona designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse
AT harazinandras designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse
AT delimariaa designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse
AT budaiszucsmaria designandoptimizationofnanostructuredlipidcarriercontainingdexamethasoneforophthalmicuse